Intellia Therapeutics (NTLA) Other Non Operating Income (2021 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Other Non Operating Income of $4.3 million for Q1 2026, down 33.61% year-over-year from $6.5 million in Q1 2025, and up 47.09% quarter-over-quarter from $2.9 million in Q4 2025.
Intellia Therapeutics (NTLA) Other Non Operating Income (2021 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Other Non Operating Income for 6 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 33.61% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $26.1 million (up 72.37% YoY), while the FY2025 annual figure was $28.3 million, up 85.64% from the prior year.
- Other Non Operating Income climbed to $4.3 million in Q1 2026 per NTLA's latest filing, from $2.9 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $10.2 million in Q3 2025 and bottomed at -$7.9 million in Q2 2024.
- Historically, Other Non Operating Income has averaged $3.9 million across 5 years, with a median of $6.6 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 2306.02% — and 2023, when it soared 464.03%.
- Intellia Therapeutics' Other Non Operating Income stood at -$3.3 million in 2022, then soared by 332.86% to $7.7 million in 2023, then declined by 2.35% to $7.5 million in 2024, then sank by 61.27% to $2.9 million in 2025, then soared by 47.09% to $4.3 million in 2026.
- Business Quant data shows NTLA's Other Non Operating Income at $4.3 million in Q1 2026, $2.9 million in Q4 2025, and $10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.13 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 2.92 Mn |
| Sep 30, 2025 | 10.15 Mn |
| Jun 30, 2025 | 8.74 Mn |
| Mar 31, 2025 | 6.48 Mn |
| Dec 31, 2024 | 7.55 Mn |
| Sep 30, 2024 | 9.06 Mn |
| Jun 30, 2024 | -7.93 Mn |
| Mar 31, 2024 | 6.57 Mn |
| Dec 31, 2023 | 7.73 Mn |
| Sep 30, 2023 | 8.88 Mn |
| Jun 30, 2023 | 8.65 Mn |
| Mar 31, 2023 | 8.83 Mn |
| Dec 31, 2022 | -3.32 Mn |
| Sep 30, 2022 | -7.70 Mn |
| Jun 30, 2022 | -2.38 Mn |
| Mar 31, 2022 | -2.63 Mn |
| Dec 31, 2021 | -822,000.00 |
| Sep 30, 2021 | 349,000.00 |